Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Inogen Price Performance
Shares of Inogen stock opened at $31.00 on Thursday. Inogen has a 52-week low of $22.51 and a 52-week high of $63.05. The firm has a market capitalization of $708.85 million, a PE ratio of -24.80 and a beta of 1.02. The company's fifty day moving average price is $26.89 and its two-hundred day moving average price is $28.42.
Inogen (NASDAQ:INGN - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.24. The firm had revenue of $103.38 million during the quarter, compared to analyst estimates of $100.64 million. Inogen had a negative net margin of 8.03% and a negative return on equity of 5.35%. The company's quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.22 earnings per share. Analysts predict that Inogen will post -1.64 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on INGN shares. Stifel Nicolaus reduced their price objective on Inogen from $40.00 to $30.00 in a research report on Monday, May 9th. StockNews.com upgraded shares of Inogen from a "sell" rating to a "hold" rating in a research report on Friday, August 5th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, Inogen has a consensus rating of "Hold" and an average target price of $41.00.